IMRX Share Price Performance
US$5.02
3.22 (178.89%)
70.8% undervalued intrinsic discount
US$17.17
Fair Value
Price US$5.02
AnalystConsensusTarget US$17.17
AnalystHighTarget US$30.00
Fair ValueUS$17.17
Share Pricen/a
Immuneering Corporation Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
IMRX Community Narratives
AN
Fair Value US$17.17 70.8% undervalued intrinsic discount
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$30 83.3% undervalued intrinsic discount
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$30
83.3% undervalued intrinsic discount
Fair Value
Profit Margin
12.33%
Future PE
105.5x
Price in 2029
US$0
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$17.17
70.8% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
402.88x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Fair Value: US$30 83.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Fair Value: US$17.17 70.8% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Immuneering Corporation Key Details
About IMRX
- Founded
- 2008
- Employees
- 53
- CEO
- WebsiteView website
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Recent IMRX News & Updates
